06-08-2020
The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Illumina, Federal Circuit, DNA, pregnancy, biotechnology, Roche, Ariosa, foetal, patents, court, ruling, en banc
Roche urges SCOTUS to cancel Illumina patent win
08-01-2021
Fed Circuit throws out doctors’ patent suit
17-08-2020
McDermott hires Boston pair from Polsinelli
12-08-2020
Roche accuses competitor of infringing diabetes patent
22-06-2020
Fed Circuit restores two Illumina DNA patents in blow to Roche
19-03-2020
